NanoViricides' NV-387 Shows No Adverse Effects in Juvenile Mouse Study

By Public Technologies
  • NanoViricides reported Oct. 20, 2026, that its antiviral candidate NV-387 showed no treatment-related adverse effects in a juvenile mouse study.
  • The highest tested dose was 1,230 mg/kg three times daily, totaling 3,690 mg/kg/day over 12 days.
  • No mortality or systemic toxicity occurred; a maximum tolerated dose could not be determined because the highest dose was well tolerated.
  • The study included a 14-day recovery period to assess persistent, reversible or delayed treatment effects.
  • NV-387 oral gummies are currently in separate Phase II trials for Ebola and Mpox in the Democratic Republic of Congo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610200845ACCESSWRNAPR_____1238833) on October 20, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.